Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People
Key facts
- Who runs it
- Medical University of South Carolina
- Where
- Charleston, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 15 people enrolled
- Started
- 6 Aug 2024
- Ended
- 13 Jan 2026
- Type of study
- Interventional
- Treatments tested
- Empowering Pregnant Women and People Receiving Medications for Opioid Use Disorder
- Record updated
- 27 March 2026
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Currently pregnant and less than 33 weeks gestational age,
- History of OUD within past 3 years,
- Confirmed prescription for sublingual buprenorphine products (i.e., Suboxone, Subutex, Zubsolv) for the purpose of treating OUD,
- Living in the United States,
- Between 18-45 years of age
Who cannot take part
- High-risk pregnancies including the following conditions: hyperemesis defined as hospitalization for intractable nausea and vomiting, hypertensive disorders of pregnancy (e.g., gestational hypertension, preeclampsia), placenta previa, or vaginal bleeding in current pregnancy after the first trimester
- Experiencing cognitive or emotional impairment that precludes providing informed consent
- Carrying multiples (i.e., twins, triplets, etc.)
- Current psychotic symptoms and/or active suicidal intent
- Incarcerated/pending incarceration or institutionalized during the study period
Where in United States
- Medical University of South CarolinaCharleston, United States
About the trial
What the trial wants to find out
This study involves testing how useful a technology-enhanced intervention is for pregnant people prescribed buprenorphine for the management of opioid use disorder. The intervention being studied is a brief therapy protocol and a mobile application. Participation involves four 60-minute therapy appointments during pregnancy, and four 30-minute therapy appointments at the end of pregnancy through 3 months postpartum. The mobile application will be accessible for at least the duration of the study. Participants will also be asked to complete questionnaires at enrollment and again at 1-month postpartum and 3-months postpartum, will send monthly photos of their prescription bottle/box, and will be contacted randomly throughout the study to perform a medication count. The total duration of the study is between 5-9 months depending on when you enroll (early second trimester-mid third trimester). Compensation is provided.
The group in the trial
- Empowering Pregnant Women and People Receiving Medications for Opioid Use DisorderTreatment being tested
EMPWR is a two-pronged intervention model comprised of 1) a provider-driven, telemedicine-based behavioral intervention to mitigate anxiety sensitivity and sleep deficiency and enhance peripartum buprenorphine retention, and 2) an adjunctive mobile application to promote patients' buprenorphine adherence and use of therapy skills learned through the behavioral intervention. The EMPWR therapy protocol is comprised of five 30-60-minute sessions delivered weekly or biweekly by a therapist during the second and/or third trimester of pregnancy, and three 30-minute booster sessions delivered months 1-3 postpartum.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- EMPWR Pilot Trial: Treatment Retention in Medication for Opioid Use Disorder Among Pregnant and Postpartum Women
- Record updated
- 27 March 2026